Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

October 31, 2009

Conditions
Excessive Sleepiness
Interventions
DRUG

Armodafinil

Armodafinil once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.

DRUG

Placebo

Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.

Trial Locations (9)

12215

Beth Israel Deaconess Medical, Boston

27612

Wake Research Associates, Raleigh

27710

Duke University Medical Center, Durham

63108

Washington University, St Louis

92103

Pacific Research, San Diego

92161

VA San Diego Healthcare System, San Diego

94010

Peninsula Sleep Center, Burlingame

94305

Stanford University, Stanford

02459

Neurocare, Inc., Newton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cephalon

INDUSTRY

NCT00711516 - Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance | Biotech Hunter | Biotech Hunter